About TISSIUM
TISSIUM is a company based in Paris (France) founded in 2013 by Jeffrey Karp.. TISSIUM has raised $155.98 million across 5 funding rounds from investors including BNP Paribas, Bpifrance and European Investment Fund. TISSIUM offers products and services including Biomorphic Polymers, Peripheral Nerve Solutions, Cardiovascular Solutions, and Gastrointestinal Solutions. TISSIUM operates in a competitive market with competitors including Laminate Medical, Vivasure Medical, Cardival Medical, Saranas and Aziyo Biologics, among others.
- Headquarter Paris, France
- Founders Jeffrey Karp
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Tissium
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$155.98 M (USD)
in 5 rounds
-
Latest Funding Round
$4.54 M (USD), Debt – Conventional
Jun 15, 2023
-
Investors
BNP Paribas
& 13 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TISSIUM
TISSIUM offers a comprehensive portfolio of products and services, including Biomorphic Polymers, Peripheral Nerve Solutions, Cardiovascular Solutions, and Gastrointestinal Solutions. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Programmable materials for tissue reconstruction in surgery
Tools for repairing peripheral nerves using polymers
Polymers for cardiovascular tissue integration
Applications for gastrointestinal tissue reconstruction
Unlock access to complete
Unlock access to complete
Funding Insights of TISSIUM
TISSIUM has successfully raised a total of $155.98M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $4.54 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Debt – Conventional — $4.5M
-
First Round
First Round
(20 Nov 2019)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2023 | Amount | Debt – Conventional - TISSIUM | Valuation |
investors |
|
| May, 2023 | Amount | Series D - TISSIUM | Valuation |
investors |
|
| Aug, 2021 | Amount | Series C - TISSIUM | Valuation | Cathay Capital , Sofinnova Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TISSIUM
TISSIUM has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include BNP Paribas, Bpifrance and European Investment Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term capital is provided by ISALT to French enterprises.
|
Founded Year | Domain | Location | |
|
Pivate equity firm that focuses on investing in healthcare and nutrition companies
|
Founded Year | Domain | Location | |
|
Cathay Capital is engaged in global investment and transformation.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TISSIUM
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TISSIUM
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tissium Comparisons
Competitors of TISSIUM
TISSIUM operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laminate Medical, Vivasure Medical, Cardival Medical, Saranas and Aziyo Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AV fistula maturation and patency are supported by VasQ device.
|
|
| domain | founded_year | HQ Location |
Bioabsorbable implants and delivery systems for arteriotomy closure are developed.
|
|
| domain | founded_year | HQ Location |
A device for vascular access management is developed.
|
|
| domain | founded_year | HQ Location |
A device is developed for detecting internal bleeding during catheterization.
|
|
| domain | founded_year | HQ Location |
Regenerative medicine products are developed for orthopedic and cardiovascular applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tissium
Frequently Asked Questions about TISSIUM
When was TISSIUM founded?
TISSIUM was founded in 2013 and raised its 1st funding round 6 years after it was founded.
Where is TISSIUM located?
TISSIUM is headquartered in Paris, France.
Is TISSIUM a funded company?
TISSIUM is a funded company, having raised a total of $155.98M across 5 funding rounds to date. The company's 1st funding round was a Series C of $58.99M, raised on Nov 20, 2019.
What does TISSIUM do?
TISSIUM was founded in 2013 in Paris, France, where focus is placed on the medical device sector for vascular applications. Biomorphic and programmable polymers are developed to support natural tissue healing. The flagship product, SETALIUM, is formulated as a biocompatible and biodegradable sealant, activated on demand to facilitate hemostasis in open vascular surgery. Operations emphasize innovation in surgical adhesives for improved procedural outcomes.
Who are the top competitors of TISSIUM?
TISSIUM's top competitors include Vivasure Medical, Cardival Medical and Aziyo Biologics.
What products or services does TISSIUM offer?
TISSIUM offers Biomorphic Polymers, Peripheral Nerve Solutions, Cardiovascular Solutions, and Gastrointestinal Solutions.
Who are TISSIUM's investors?
TISSIUM has 14 investors. Key investors include BNP Paribas, Bpifrance, European Investment Fund, ISALT, and Merieux Equity Partners.